Pascal Deschatelets - 21 May 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: APLS
Reported as of: 21 May 2025
Net transaction value: +$48,053
SEC form: 4
Accepted by SEC: 22 May 2025, 13:19:03 UTC
Prior SEC filing: 30 Jan 2025
Next SEC filing: 11 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 22 May 2025.

Key facts

This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 May 2025, 13:19.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001657720 Primary reporting owner

Relationship: Chief Scientific Officer
Address: C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Signature date: 22 May 2025

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Options Exercise

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Options Exercise

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

This stock option was granted on 02/08/2016 and is fully vested.